摘要
目的:研究Smad4和转化生长因子β受体Ⅱ(TβR-Ⅱ)在宫颈腺癌中的表达及其与临床病理的相关性,探讨其作为宫颈腺癌预后判断分子指标的可能性。方法:免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连接法(SP法)检测36例宫颈腺癌组织中Smad4和TβR-Ⅱ的表达,以20例正常宫颈腺上皮组织作为对照,对Smad4和TβR-Ⅱ的表达与宫颈腺癌临床病理参数的关系进行分析。结果:Smad4和TβR-Ⅱ在宫颈腺癌中的表达显著低于正常宫颈腺上皮组织(P<0.05),在低分化癌中的表达率显著低于中高分化癌(P<0.05),在有淋巴结转移组显著低于无淋巴结转移组(P<0.05)。Smad4和TβR-Ⅱ的表达相关。结论:Smad4和TβR-Ⅱ的表达缺失与宫颈腺癌的发生、分化程度及转移有关。Smad4和Tβ-Ⅱ的低表达可能作为判断宫颈腺癌恶性程度和转移的标记,Smad4和TβR-Ⅱ联合检测能作为一种有效的肿瘤标记物用于宫颈腺癌患者预后的评估。
Objective： To study the correlation of the expression of Smad4 and TGF-β receptor Ⅱ（TβR-Ⅱ） with clinical pathology in cervical adenocarcinoma,and to explore its possibility as a marker to decide the prognosis of cervical adenocarcinoma.Methods： To detect the expression of Smad4 and TβR-Ⅱin 36 cases of cervical adenocarcinoma and 20 cases of normal cervical glandular epithelium tissue and to investigate the relation between the expression of Smad4 with TβR-Ⅱand clinical pathology. Results： The expression of Smad4 and TβR-Ⅱ in cervical adenocarcinoma is significantly lower than normal cervical glan-dular epithelium tissue （ P 〈 0.05 ）. The expression of Smad4 and TβR-Ⅱ in cervical adenocarcinoma with poor differentiated was significantly lower than that of moderate or well differentiated （ P 〈 0.05 ）. The expression of Smad4 and TβR-Ⅱ is significantly lower in cervical adenocarcinoma with metastatic lymph nodes than in the tissue with no metastatic lymph nodes （ P 〈 0.05 ）. The expression of Smad4 and TβR-Ⅱ was significantly related with clinical stage （P 〈 0.05 ）. Conclusion： The deleted expression of Smad4 and TβR-Ⅱ was associated with development, advanced, differentiated and metastasis in cervical adenocarcinoma. Smad4 and TβR-Ⅱ may be tect Smad4 and TβR-Ⅱmay be a marker for differentiated and metastasis of cervical adenocarcinoma. To dea useful tumor marker to decide the prognosis of cervical adenocarcinoma
出处
《江苏大学学报（医学版）》
CAS
2009年第5期425-427,432,共4页
Journal of Jiangsu University：Medicine Edition
